Coleus (Makandi) for Asthma Support

Research suggests that Coleus forskohlii and its primary active compound forskolin have recognized potential in supporting asthma management, with the available evidence drawing from animal model experiments, ethnobotanical records, and multiple narrative reviews. Studies indicate that a 2019 experimental study using animal models demonstrated that Coleus forskohlii extracts may relieve asthma-related symptoms through modulation of inflammation and extracellular matrix activity, while several reviews published between 2010 and 2024 consistently describe forskolin's commercial and therapeutic use for asthma as well-established. The body of evidence is supportive in direction, but it is worth noting that the current literature relies heavily on reviews and preclinical data rather than robust human clinical trials such as randomized controlled trials or meta-analyses, which represents a meaningful limitation in drawing firm conclusions about efficacy in people. Readers interested in this area should be aware that traditional and ethnobotanical uses across related Coleus species add historical context but do not substitute for controlled human evidence.